Article Text

Download PDFPDF
Montelukast moderately decreased asthma symptoms in children with persistent asthma

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In children with persistent asthma, is montelukast a well tolerated and effective therapeutic option?


Randomised {allocation concealed*}, blinded (patients, clinicians, and {data collectors}),* placebo controlled trial with 12 weeks of follow up.


93 centres in Africa, Australia, Europe, North America, and South America.


689 children who were 2 to 5 years of age (mean age 4 y, 59% boys, 56% white), had ≥ 3 episodes of asthma symptoms in the previous year, had a total asthma symptom score ≥ 1 (of 24) for ≥ 8 days during the 2 week placebo baseline period, and used β agonists for ≥ 8 days during the placebo baseline period. Exclusion criteria included asthma intubation and emergency department treatment or admission …

View Full Text


  • * See glossary.

  • Information provided by author.

  • p Values provided by author.

  • Source of funding: Merck Research Laboratories.

  • For correspondence: Dr B Knorr, Respiratory & Allergy, Merck Research Laboratories, Rahway, NJ, USA.